Evidence map›Paper›PMID 32578147›Full record

ReviewAdvances in neurobiology2020

Investigation of Schizophrenia with Human Induced Pluripotent Stem Cells.

Samuel K Powell, Callan P O'Shea, Sara Rose Shannon, Schahram Akbarian, Kristen J Brennand

Abstract readReview
In one paragraph

Review in Advances in neurobiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Use ofFrontiers in cellular and infection microbiology · 2023
    Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Samuel K PowellMedical Scientist Training Program, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Callan P O'SheaFriedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Sara Rose ShannonFriedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Schahram AkbarianFriedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Kristen J BrennandFriedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. kristen.brennand@mssm.edu.

Funding

Higher Order Chromatin and Genetic Risk for SchizophreniaR01MH106056 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI AKBARIAN, SCHAHRAM, BRENNAND, KRISTEN JENNIFER · 2015 to 2023
$6.7M
Functional genomic resource and integrative model of dopaminergic circuitry associated with psychiatric diseaseU01DA048279 · NIDA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI AKBARIAN, SCHAHRAM, BRENNAND, KRISTEN JENNIFER · 2019 to 2023
$3.5M
Modeling the contribution of common variants to schizophrenia riskR56MH101454 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BRENNAND, KRISTEN JENNIFER, HUCKINS, LAURA MARIANNE · 2018 to 2019
$1.5M
NIDA NIH HHS U01 DA048279NIMH NIH HHS R01 MH106056NIMH NIH HHS R56 MH101454
6 · The paper itself

Abstract

Schizophrenia is a chronic and severe neuropsychiatric condition manifested by cognitive, emotional, affective, perceptual, and behavioral abnormalities. Despite decades of research, the biological substrates driving the signs and symptoms of the disorder remain elusive, thus hampering progress in the development of treatments aimed at disease etiologies. The recent emergence of human induced pluripotent stem cell (hiPSC)-based models has provided the field with a highly innovative approach to generate, study, and manipulate living neural tissue derived from patients, making possible the exploration of fundamental roles of genes and early-life stressors in disease-relevant cell types. Here, we begin with a brief overview of the clinical, epidemiological, and genetic aspects of the condition, with a focus on schizophrenia as a neurodevelopmental disorder. We then highlight relevant technical advancements in hiPSC models and assess novel findings attained using hiPSC-based approaches and their implications for disease biology and treatment innovation. We close with a critical appraisal of the developments necessary for both further expanding knowledge of schizophrenia and the translation of new insights into therapeutic innovations.

Indexed as

Induced Pluripotent Stem CellsSchizophreniaHumansNeuronsCRISPR genome engineeringDisease modelingHuman induced pluripotent stem cellsPsychiatric genomicsSchizophrenia

Identifiers

PMID32578147
PMCPMC8033573

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.